Table 3 Characteristics of the study population stratified for whether textbook outcomes were achieved after splenectomy.
From: Textbook outcomes after splenectomy in patients with portal hypertension
Variable | Textbook outcome (n = 139) | Non-textbook outcome (n = 124) | P-Value |
|---|---|---|---|
Age (≥60 year) | 14 (10.07%) | 9 (7.26%) | 0.420 |
Gender (male/female) | 101/38 | 92/32 | 0.779 |
Coexisting condition | |||
Drinking | 19 (13.67%) | 14 (11.29%) | 0.561 |
Smoking | 35 (25.18%) | 30 (24.19%) | 0.853 |
Hypertension | 5 (3.60%) | 5 (4.03%) | 0.854 |
Diabetes | 9 (6.47%) | 12 (9.68%) | 0.339 |
HBV | 131 (94.24%) | 118 (95.16%) | 0.741 |
Moderate/severe gastro- esophageal varices | 86 (61.87%) | 79 (63.71%) | 0.758 |
Refractory ascites | 20 (14.39%) | 19 (15.32%) | 0.831 |
Hepatic encephalopathy | 1 (0.72%) | 1 (0.81%) | 1.000 |
Laboratory results | |||
Leucocytes (<2 × 109/L) | 54 (38.85%) | 51 (41.13%) | 0.706 |
Platelet count (<50 × 109/L) | 101 (72.66%) | 92 (74.19%) | 0.779 |
Hemoglobin (g/L) | 98.34 ± 26.47 | 95.83 ± 26.37 | 0.446 |
ALT (>40 U/L) | 86 (61.87%) | 83 (66.94%) | 0.335 |
AST (>40 U/L) | 67 (48.20%) | 69 (55.65%) | 0.197 |
Total bilirubin (µmol/L) | 24.63 ± 13.37 | 25.03 ± 12.40 | 0.800 |
Direct bilirubin (µmol/L) | 9.24 ± 6.53 | 10.31 ± 7.19 | 0.210 |
Albumin (g/L) | 35.63 ± 5.55 | 34.82 ± 6.07 | 0.263 |
Creatinine (µmol/L) | 64.35 ± 15.46 | 67.94 ± 19.51 | 0.108 |
PT (s) | 15.84 ± 2.06 | 16.88 ± 2.32 | <0.001 |
APTT (s) | 43.39 ± 8.40 | 45.50 ± 11.38 | 0.096 |
INR | 1.29 ± 0.17 | 1.38 ± 0.35 | 0.007 |
Fibrinogen (g/L) | 1.89 ± 0.58 | 1.90 ± 0.58 | 0.893 |
AFP (mg/L) | 8.08 ± 12.78 | 14.28 ± 26.41 | 0.064 |
HBV-DNA (×105, cps/ml) | 117.06 ± 1264.98 | 33.49 ± 205.20 | 0.468 |
Prognostic nutritional index | 38.45 ± 5.60 | 38.26 ± 7.58 | 0.833 |
Child-Pugh Score | 7.09 ± 1.38 | 7.43 ± 1.35 | 0.042 |
MELD score | 7.09 ± 4.21 | 7.51 ± 4.29 | 0.522 |
Intraoperative features | |||
Spleen volume (mm3) | 1253.44 ± 798.76 | 1364.79 ± 888.61 | 0.307 |
Spleen size (mm) | 156.30 ± 42.90 | 160.86 ± 36.96 | 0.483 |
Portal vein diameter (>13 mm) | 61 (43.88%) | 49 (39.52%) | 0.473 |
Splenic vein diameter (>9 mm) | 119 (85.61%) | 94 (75.81%) | 0.043 |
Intraoperative blood loss (> 400 ml) | 9 (6.47%) | 12 (9.68%) | 0.339 |
Surgical approach (Open laparotomy) | 119 (85.61%) | 108 (87.10%) | 0.726 |
Early administration of anticoagulant drugs | 28 (20.14%) | 31 (25.00%) | 0.346 |
Preoperative regular antiviral treatment | 21 (15.11%) | 30 (24.19%) | 0.063 |
Overall survival time (months) | 75.60 (52.80–120.00) | 66.00 (58.80–98.40) | 0.325 |
Overall survival (yes/no) | 120/19 | 106/18 | 0.844 |
HCC occurrence (yes/no) | 17/122 | 24/100 | 0.100 |
